Cover Image
市場調查報告書

美國的癌症疫苗的開發平台分析

US Cancer Vaccine Pipeline Analysis

出版商 PNS Pharma 商品編碼 302559
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的癌症疫苗的開發平台分析 US Cancer Vaccine Pipeline Analysis
出版日期: 2014年01月14日 內容資訊: 英文 300 Pages
簡介

癌症疫苗是缺乏有效治療法的各種類型癌症可用的選擇之一。Dendreon公司的前列腺癌疫苗「Provenge」已通過認証,讓癌症疫苗領域史無前例熱門了起來,這個新收益性高的領域預測將有許多企業加入。Merck的預防癌症用疫苗「Gardasil」、GSK的「Cervarix」更是受到全球注目的疫苗代表案例。美國癌症疫苗市場正在成長中,同時也是加入的絕佳機會。約佔全球市場50%的美國癌症疫苗市場在2012年推計市場規模為140億美金。每年將近有150萬名美國人被診斷出罹患癌症,該市場預測到2020年將達到200億美金的規模。

本報告提供美國正在開發的各種癌症疫苗詳細調查,提供各開發階段品牌名,藥物類別,相關經營者,作用機制,專利資料等彙整資料,為您概述為以下內容。

第1章 美國的癌症疫苗市場:概要

第2章 美國的癌症疫苗市場:法律規章

  • 早期·後期臨床試驗相關考察
  • 早期臨床試驗相關考察
  • 後期臨床試驗相關考察

第3章 癌症疫苗開發臨床階段:研究階段

  • 概要
  • 癌症疫苗簡介

第4章 癌症疫苗開發臨床階段:臨床試驗前

  • 概要
  • 癌症疫苗簡介

第5章 癌症疫苗開發臨床階段:臨床試驗

  • 概要
  • 癌症疫苗簡介

第6章 癌症疫苗開發臨床階段:階段0

  • 概要
  • 癌症疫苗簡介

第7章 癌症疫苗開發臨床階段:PhaseⅠ

  • 概要
  • 癌症疫苗簡介

第8章 癌症疫苗開發臨床階段:PhaseⅠ/Ⅱ

  • 概要
  • 癌症疫苗簡介

第9章 癌症疫苗開發臨床階段:PhaseⅡ

  • 概要
  • 癌症疫苗簡介

第10章 癌症疫苗開發臨床階段:PhaseⅡ/Ⅲ

  • 概要
  • 癌症疫苗簡介

第11章 癌症疫苗開發臨床階段:PhaseⅢ

  • 概要
  • 癌症疫苗簡介

第12章 上市

  • 概要
  • 已上市癌症疫苗

圖表

目錄

Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Merck's Gardasil, a Prophylactic cancer vaccine, along with GSK's Cervarix are some of the first vaccines to have gained attention globally with their blockbuster status.

The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close to 1.5 million Americans being diagnosed with cancer every year, this market is expected to o reach USD 20 billion by 2020.

"US Cancer Vaccine Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various vaccines being developed for the treatment of various cancers. Research report covers all vaccines being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US cancer vaccine market based upon development process.

Following parameters for each orphan designated drug profile in development phase are covered in "US Cancer Vaccine Pipeline Analysis" research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Orphan Designation by Indication, Country & Organisation
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • ATC Codes

US Cancer Vaccine Pipeline by Clinical Phase:

  • Research: 2
  • Preclinical: 38
  • Clinical: 2
  • Phase-0: 1
  • Phase-I: 35
  • Phase-I/II: 19
  • Phase-II: 32
  • Phase-II/III: 2
  • Phase-III: 17
  • Marketed: 5

Table of Contents

1. US Cancer Vaccine Market Overview

2. US Cancer Vaccine Market Regulations

  • 2.1. Considerations for Both Early and Late Phase Clinical Trials
  • 2.2. Considerations for Early Phase Clinical Trials
  • 2.3. Considerations For Late Phase Clinical Trials

3. Cancer Vaccine Development Clinical Phase: Research

  • 3.1. Overview
  • 3.2. Cancer Vaccine Profile in Clinical Phase

4. Cancer Vaccine Development Clinical Phase: Preclinical

  • 4.1. Overview
  • 4.2. Cancer Vaccine Profile in Clinical Phase

5. Cancer Vaccine Development Clinical Phase: Clinical

  • 5.1. Overview
  • 5.2. Cancer Vaccine Profile in Clinical Phase

6. Cancer Vaccine Development Clinical Phase: Phase-0

  • 6.1. Overview
  • 6.2. Cancer Vaccine Profile in Clinical Phase

7. Cancer Vaccine Development Clinical Phase: Phase-I

  • 7.1. Overview
  • 7.2. Cancer Vaccine Profile in Clinical Phase

8. Cancer Vaccine Development Clinical Phase: Phase-I/II

  • 8.1. Overview
  • 8.2. Cancer Vaccine Profile in Clinical Phase

9. Cancer Vaccine Development Clinical Phase: Phase-II

  • 9.1. Overview
  • 9.2. Cancer Vaccine Profile in Clinical Phase

10. Cancer Vaccine Development Clinical Phase: Phase-II/III

  • 10.1. Overview
  • 10.2. Cancer Vaccine Profile in Clinical Phase

11. Cancer Vaccine Development Clinical Phase: Phase-III

  • 11.1. Overview
  • 11.2. Cancer Vaccine Profile in Clinical Phase

12. Marketed

  • 12.1. Overview
  • 12.2. Marketed Cancer Vaccine Profile

List of Table

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top